Cargando…
Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were cat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357264/ https://www.ncbi.nlm.nih.gov/pubmed/22522615 http://dx.doi.org/10.2337/db11-1509 |
_version_ | 1782233649364598784 |
---|---|
author | Sung, Jia-Ying Park, Susanna B. Liu, Ya-Ting Kwai, Natalie Arnold, Ria Krishnan, Arun V. Lin, Cindy S.-Y. |
author_facet | Sung, Jia-Ying Park, Susanna B. Liu, Ya-Ting Kwai, Natalie Arnold, Ria Krishnan, Arun V. Lin, Cindy S.-Y. |
author_sort | Sung, Jia-Ying |
collection | PubMed |
description | To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0–1 [n = 35]), grade 1 (TNS 2–8 [n = 42]), and grade 2/3 (TNS 9–24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction. |
format | Online Article Text |
id | pubmed-3357264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-33572642013-06-01 Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes Sung, Jia-Ying Park, Susanna B. Liu, Ya-Ting Kwai, Natalie Arnold, Ria Krishnan, Arun V. Lin, Cindy S.-Y. Diabetes Complications To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0–1 [n = 35]), grade 1 (TNS 2–8 [n = 42]), and grade 2/3 (TNS 9–24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction. American Diabetes Association 2012-06 2012-05-14 /pmc/articles/PMC3357264/ /pubmed/22522615 http://dx.doi.org/10.2337/db11-1509 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Complications Sung, Jia-Ying Park, Susanna B. Liu, Ya-Ting Kwai, Natalie Arnold, Ria Krishnan, Arun V. Lin, Cindy S.-Y. Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes |
title | Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes |
title_full | Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes |
title_fullStr | Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes |
title_full_unstemmed | Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes |
title_short | Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes |
title_sort | progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes |
topic | Complications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357264/ https://www.ncbi.nlm.nih.gov/pubmed/22522615 http://dx.doi.org/10.2337/db11-1509 |
work_keys_str_mv | AT sungjiaying progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes AT parksusannab progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes AT liuyating progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes AT kwainatalie progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes AT arnoldria progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes AT krishnanarunv progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes AT lincindysy progressiveaxonaldysfunctionprecedesdevelopmentofneuropathyintype2diabetes |